Nurix Therapeutics Shares Plunge 28.4% as Sanofi Terminates STAT6 Drug Development Programme

Nurix Therapeutics (NASDAQ:NRIX) shares plunged 28.4% in premarket trading on Wednesday after pharmaceutical partner Sanofi announced plans to discontinue the Phase 1 clinical trial of SAR448272, an investigational oral STAT6 degrader, and terminate the associated development programme.

The decision, disclosed after Tuesday’s market close, removes Nurix’s eligibility for future development, regulatory and commercial milestone payments, as well as royalties associated with the discontinued drug candidate.

The announcement prompted Jefferies to lower its 12-month price target for Nurix from $45 to $36, although the investment firm maintained its Buy rating.

Despite the setback, Nurix confirmed that its existing cash runway guidance remains unchanged, with approximately $1.1 billion in cash, cash equivalents and marketable securities as of late August 2026.

Sanofi Discontinues Phase 1 Trial of SAR448272

Sanofi informed Nurix of its decision to discontinue the Phase 1 first-in-human clinical trial evaluating SAR448272, an oral STAT6 protein degrader.

The pharmaceutical company also decided to terminate the development programme in its entirety.

SAR448272 was being developed under a collaboration agreement between Nurix and Sanofi, with the programme forming part of their broader research partnership.

STAT6 is a protein involved in cellular signalling pathways associated with immune responses and inflammation, making it a potential target for therapeutic development.

The investigational treatment was designed to degrade STAT6 rather than simply inhibit its activity.

The termination represents a setback for Nurix’s partnered development portfolio, removing a programme that had progressed into human clinical testing.

Sanofi has not provided a detailed public scientific explanation for the decision, leaving uncertainty about the factors that influenced the termination.

Nurix Loses Potential Milestone Payments and Royalties

The discontinuation has financial implications for Nurix under its existing collaboration agreement with Sanofi.

Following the termination of SAR448272, Nurix will no longer be eligible to receive future development, regulatory or commercial milestone payments associated with the programme.

The company will also lose eligibility for potential royalties on future sales of the drug candidate.

Such payments can represent an important source of future revenue for biotechnology companies that license investigational treatments to larger pharmaceutical partners.

Milestone payments are generally linked to the achievement of specified development, regulatory or commercial objectives, while royalties depend on future product sales.

The termination therefore eliminates potential future income associated with SAR448272.

However, these payments were contingent on the programme achieving its development objectives and were not guaranteed.

The announcement does not establish that Nurix will incur an immediate cash loss equivalent to the value of the discontinued milestones.

Nevertheless, the removal of a partnered clinical asset has reduced the company’s potential future revenue opportunities.

Sanofi Indicates No Immediate Patient Safety Concern

The reasons behind Sanofi’s decision remain unclear.

According to information highlighted by Jefferies, Nurix management had not reviewed the clinical or preclinical data underlying the decision at the time of the announcement.

Sanofi indicated that the discontinuation was not associated with an immediate patient safety concern.

However, the absence of an identified immediate safety issue does not establish the precise reason for terminating the programme.

Drug development decisions can involve several considerations, including clinical findings, development priorities and commercial assessments.

In this case, the available information does not identify which factors were decisive.

The limited explanation has added to investor uncertainty because it remains unclear whether the decision reflects programme-specific findings or broader strategic considerations.

Further clarification from Sanofi or Nurix could help investors assess the implications for the companies’ remaining collaboration activities.

Jefferies Cuts Nurix Price Target to $36

The termination prompted Jefferies to revise its valuation of Nurix Therapeutics.

On November 4, the investment firm reduced its 12-month price target to $36 from $45, representing a 20% decrease.

Despite the reduction, Jefferies maintained its Buy rating on the biotechnology company’s shares.

The firm described Sanofi’s decision as unexpected and highlighted the lack of clarity surrounding the reasons for discontinuing SAR448272.

Jefferies also noted that Nurix management had not seen the clinical or preclinical information supporting Sanofi’s decision.

The reduced price target reflects a reassessment of the company’s development portfolio following the loss of the partnered asset.

However, the decision to retain a Buy rating suggests that Jefferies continues to see potential value in Nurix’s remaining programmes and financial position.

The analyst action added to market attention surrounding the announcement as investors reassessed the company’s longer-term development prospects.

Nurix Maintains Cash Runway Into Second Half of 2029

Despite the clinical development setback, Nurix confirmed that its cash runway guidance remains unchanged.

The company reported approximately $1.1 billion in cash, cash equivalents and marketable securities as of late August 2026.

Management expects these financial resources to support operations into the second half of 2029.

The substantial cash position provides Nurix with funding to continue advancing its remaining research and clinical development programmes.

For clinical-stage biotechnology companies, liquidity is particularly important because drug development can require substantial investment before a treatment generates commercial revenue.

A longer cash runway can reduce the immediate need for additional financing, although future spending requirements and development decisions may affect funding needs.

Nurix’s confirmation that its cash runway remains intact indicates that the termination of SAR448272 has not changed its current financing outlook.

The company’s financial resources therefore remain an important consideration as investors assess the impact of the discontinued programme.

Broader Sanofi Collaboration Remains Active

Although Sanofi has terminated the SAR448272 programme, its wider collaboration with Nurix remains in place.

Nurix continues to be eligible for potential milestone payments and royalties associated with other licensed programmes covered by the partnership.

The distinction is important because the termination affects a specific investigational asset rather than ending the companies’ entire research relationship.

The remaining programmes could continue to provide development opportunities and potential future revenue, subject to their individual progress and contractual terms.

However, the financial contribution of those programmes remains uncertain and will depend on future research, clinical and commercial outcomes.

Investors will be monitoring whether the decision concerning SAR448272 has any implications for the broader collaboration.

At present, the company has indicated that the remaining partnership activities are continuing.

Bexobrutinib and NX-1607 Remain Important Pipeline Assets

Nurix’s development portfolio continues to include its investigational drug candidates bexobrutinib and NX-1607.

These programmes remain important components of the company’s clinical development strategy following the termination of SAR448272.

Nurix focuses on developing medicines that target proteins involved in disease processes, including treatments based on targeted protein degradation.

Its remaining clinical pipeline provides opportunities for the company to advance additional drug candidates independently of the discontinued Sanofi programme.

However, the success of these treatments will depend on future clinical results, regulatory decisions and development progress.

The termination of SAR448272 increases the importance of Nurix’s remaining assets in determining its longer-term prospects.

Investors will therefore be paying particular attention to future clinical updates involving bexobrutinib and NX-1607.

Nurix Declines Amid Broader Premarket Weakness

Nurix’s 28.4% premarket decline occurred against a weaker backdrop for US equity futures.

Investors were assessing uncertainty surrounding the US midterm election results, with early vote counts indicating the possibility of a change in congressional control.

The broader selling pressure contributed to a cautious trading environment.

However, the magnitude of Nurix’s decline indicated that the Sanofi announcement was the principal company-specific catalyst.

The loss of a partnered clinical programme, combined with uncertainty surrounding the termination decision and the subsequent analyst price target reduction, prompted a substantial reassessment of the company’s prospects.

The broader market environment may have influenced trading sentiment, but the clinical development setback remained the central factor behind the sharp share price movement.

Outlook for Nurix Therapeutics

Nurix Therapeutics faces renewed uncertainty following Sanofi’s decision to terminate the SAR448272 clinical development programme.

The discontinuation removes potential future milestone payments and royalties associated with the investigational STAT6 degrader and reduces the number of partnered clinical assets in Nurix’s development portfolio.

Jefferies responded by cutting its 12-month price target from $45 to $36 while maintaining a Buy rating, highlighting both the unexpected nature of the decision and the lack of a detailed explanation.

However, Nurix retains a substantial financial position, with approximately $1.1 billion in cash, cash equivalents and marketable securities as of late August 2026.

The company continues to expect its existing resources to fund operations into the second half of 2029, while its broader collaboration with Sanofi remains active.

Future developments involving bexobrutinib, NX-1607 and other licensed programmes will be important in determining the company’s longer-term outlook.

Investors will also be monitoring whether additional information emerges concerning Sanofi’s decision to discontinue SAR448272.

Although the termination represents a significant setback, Nurix’s remaining clinical pipeline and financial resources provide a foundation for continued development activities.

Nurix Therapeutics stock price